This miR‐16 suppresses CSF‐1 and CCL‐2 expression, reprogramming tumor‐associated macrophages (TAMs) via reduced TGF‐β and IL‐6 levels and elevated TNF‐α through the NF‐κB pathway. The gene discussed is TGFB1; the disease is neoplasm.